Mid-Sized European M&A Fills Earnings Gap--And More?
Executive Summary
Solvay's acquisition of France's Fournier suggests that there is value within Europe's family-owned, domestically-focused groups, and at good prices. The deal will boost Solvay's earnings until its own pipeline matures, although some question the potential for longer-term synergies.
You may also be interested in...
Reviewing 2005: The Top Biopharma Stories
Among our stop stories from 2005: Safety and the FDA: decision by indecision; ahe Plan B kerfuffle; acquisition as the new exit strategy for private biotechs; TLRs-the hottest drug target; pricing revives vaccines; Pfizer's challenges and Genentech's triumphs. Among the predictions for the big stories of 2006: Medicare's impact, the oncology bubble, biogenerics and genomics' revival--via diagnostics.
Reviewing 2005: The Top Biopharma Stories
Among our stop stories from 2005: Safety and the FDA: decision by indecision; ahe Plan B kerfuffle; acquisition as the new exit strategy for private biotechs; TLRs-the hottest drug target; pricing revives vaccines; Pfizer's challenges and Genentech's triumphs. Among the predictions for the big stories of 2006: Medicare's impact, the oncology bubble, biogenerics and genomics' revival--via diagnostics.
Pierre Fabre: Time to Reap R&D Rewards In-House
Recent Big Pharma deals validate Pierre Fabre's productive research, and underline mid-sized pharmas' importance as a product source. But the French group hasn't yet fully capitalized on its R&D.